On January 23, 2026, Romeo R. Dizon, the Chief Financial Officer of Iridex Corporation (NASDAQ: IRIX), completed a purchase of 5,221 common shares. The acquisitions were made at an average cost of $1.4779 per share, summing to an overall transaction value of approximately $7,716. This activity occurred as Iridex's shares have experienced notable momentum, delivering a 5.67% gain over the last week and exceeding a 30.7% rise since the beginning of the year, based on InvestingPro data.
The transaction involved multiple purchases with prices ranging narrowly between $1.475 and $1.48 per share. Following this transaction, Dizon's direct holdings in Iridex amount to 105,661 shares. Currently, Iridex's stock trades at about $1.57, slightly above Dizon's buying cost. InvestingPro analysis suggests that despite the recent gains, the stock may still be modestly undervalued.
Financially, Iridex faces challenges, as indicated by a net loss of $0.30 per share over the trailing twelve months and swift cash consumption, factors captured in the comprehensive Pro Research Report for this company, which holds a market capitalization near $26.56 million.
Adding to the financial context, Iridex recently released preliminary unaudited results for the fourth quarter. The figures point to revenues estimated between $14.6 million and $14.8 million, representing a 15% to 17% increase relative to the comparable period last year, alongside achieving positive cash flow for the quarter. Additionally, Iridex anticipates reporting a positive adjusted EBITDA figure for the entirety of 2025.
On the innovation front, an independent study published in the journal Ophthalmology and Therapy highlighted Iridex's MicroPulse transscleral laser technology's efficacy in glaucoma retreatment, demonstrating intraocular pressure reductions between approximately 25% and 35% among patients evaluated.
The company disclosed a net loss in the previous quarter (Q3 2025) amounting to $1.6 million, or $0.09 per share, which underperformed analysts' expectations of a $0.06 loss per share. Revenue for that quarter was reported at $12.5 million, below the forecasted $13.1 million. While these financial outcomes present some concerns, ongoing advances in technology and positive revenue trends offer potential avenues for future improvement.